Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%

Novo Nordisk said Hims & Hers has "failed to adhere to the law which prohibits mass sales of compounded drugs" under the "false guise" of personalization. Read More

Novo Nordisk's Stellar Wegovy-Fuelled Run of Hiking Sales Guidance Could Be Ending - U.S. News

LONDON (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year. But recent weak U.S. prescription ... Read More

Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing"

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug. Read More

How Novo Nordisk misread the US market for its weight loss sensation

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ... Read More

From Insulin to Ozempic, History of Novo Nordisk's CEOs - U.S. News

Novo Nordisk launches its first GLP-1 product, liraglutide, branded as Victoza in 2009 in Europe and in 2010 in the U.S. In 2013, Novo Nordisk's semaglutide starts global phase 3 trials. Read More

Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar — Update - Morningstar

The GLP-1 products, including Novo Nordisk's Wegovy and Ozempic, have shown efficacy in the treatment of diabetes and in weight reduction, among other applications. Read More

Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook - Novo Nordisk (NYSE:NVO) - Benzinga

Q1 Wegovy sales rose 85% to DKK 17.36 billion; Ozempic up 18% to DKK 32.72 billion. Novo Nordisk's Q1 sales hit $10.89 billion, missing the $11.64 billion consensus estimate. Market-moving news ... Read More

Novo Nordisk: Nothing Has Changed, Except That It's Cheaper Now

Lilly's shares surged that same day, while Novo Nordisk's dropped by 8%. I even read comments suggesting " the moment had come and Novo had been outdone. " But let's put this into context. Read More

Novo Nordisk's stellar Wegovy-fuelled run of hiking sales guidance could be ending - Reuters

LONDON, April 24 (Reuters) - Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk (NOVOb.CO), opens new tab has raised its annual sales guidance several times a year ... Read More